论文部分内容阅读
目的:分析糖尿病患者血清25羟维生素Dn 3[25-（OH）Dn 3]表达改变及其与大血管并发症的相关性。n 方法:选择河北省沧州市中心医院2018年2月至2019年11月收治的200例糖尿病患者，依据有无大血管并发症分为有大血管并发症组87例及无大血管并发症组113例；依据25-（OH）Dn 3缺乏程度分为25-（OH）Dn 3正常组32例，轻度缺乏组94例，中重度缺乏组74例。同期选择门诊健康体检者168例作为对照组。比较糖尿病组与对照组、有大血管并发症组与无大血管并发症组血清25-（OH）Dn 3水平的差异，并分析合并糖尿病大血管并发症患者血清25-（OH）Dn 3水平与颈动脉内膜中层厚度（IMT）的相关性。n 结果:糖尿病组血清25-（OH）Dn 3水平低于对照组[（24.79 ± 3.02） μg/L比（39.18 ± 4.38） μg/L]，差异有统计学意义（n t = 37.132，n P<0.05）。糖尿病 有大血管并发症组血清25-（OH）Dn 3水平低于无大血管并发症组[（21.08 ± 2.64） μg/L比 （27.65 ± 3.31） μg/L]，IMT水平则高于无大血管并发症组[（1.29 ± 0.13）mm比（0.93 ± 0.10） mm]，差异有统计学意义（n P<0.05）。25-（OH）Dn 3正常组、轻度缺乏组、中重度缺乏组大血管并发症发生率分别为12.50%（4/32）、40.43%（38/94）、60.81%（45/74），差异有统计学意义（n χ2 = 21.896，n P<0.05）。糖尿病大血管并发症患者血清25-（OH）Dn 3水平与IMT呈负相关（n r = - 0.513，n P<0.05）。n 结论:糖尿病患者血清25-（OH）Dn 3水平有所下降，其水平变化与糖尿病患者大血管并发症的发生有关。n “,”Objective:To analyze the changes of serum 25-hydroxyvitamin Dn 3[25-(OH)Dn 3] expression in diabetic patients and its correlation with macrovascular complications.n Methods:Two hundreddiabetic patients admitted to Cangzhou Central Hospital from February 2018 to November 2019 were divided into macrovascular complications group (87 cases) and without macrovascular complicationsgroup (113 cases). According to the degree of 25-(OH)Dn 3 deficiency, 32 cases were divided into 25-(OH)Dn 3 normal group, 94 cases were mild deficiency group and 74 cases were moderate and severe deficiency group. At the same time, 168 outpatients were selected as control group. The levels of serum 25-(OH)Dn 3 were compared between diabetic group and control group, macrovascular complications group and without macrovascular complications group, and the correlation between the level of serum 25-(OH)Dn 3 and carotid intima-media thickness (IMT) was analyzed.n Results:The level of serum 25-(OH)Dn 3 in diabetic group was lower than that in control group: (24.79 ± 3.02) μg/L vs. (39.18 ± 4.38) μg/L, the difference was statistically significant ( n P<0.05). The level ofserum 25-(OH)Dn 3 in diabetic patients with macrovascular complications group was lower than that in without macrovascular complications group: (21.08 ± 2.64) μg/L vs. (27.65 ± 3.31) μg/L; while the IMT was higher than that without macrovascular complications group: (1.29 ± 0.13) mm vs. (0.93 ± 0.10) mm, the differences were statistically significant ( n P<0.05). The incidence of macrovascular complications in 25-(OH)Dn 3 moderate and severe deficiency group was higher than that in 25-(OH)Dn 3 mild deficiency group and 25-(OH)Dn 3 normal group: 60.81%(45/74) vs. 40.43%(38/94), 12.50%(4/32), the difference was statistically significant (n χ2 = 21.896, n P<0.05). The level of serum 25-(OH)Dn 3 in patients with diabetic macrovascular complications was negatively correlated with IMT (n r = -0.513, n P<0.05).n Conclusions:The level of serum 25-(OH)Dn 3 in diabetic patients is decreased, and the change of its concentration is related to the occurrence of macrovascular complications.n